news

NICE releases draft guidance for using cannabis-based medicinal products

6
SHARES

The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.

The UK National Institute for Health and Care Excellence (NICE) has released draft recommendations for the use of cannabis-based medicinal products. The guide is a result of a comprehensive evaluation of their clinical and cost-effectiveness.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The draft follows the re-classification of these products last year to allow specialist doctors to prescribe them where the needs of patients cannot be met by licensed medicines. The guidance is for the treatment of patients with intractable nausea and vomiting as a result of chemotherapy, chronic pain, spasticity and severe treatment-resistant epilepsy.

The recommendations investigate most cannabis-based medicinal products, including the Sativex, a licensed product for treating spasticity in people with multiple sclerosis (MS). It found that this product is not cost-effective so should not be prescribed for this therapy.  

The draft also says that, other than cannabidiol (CBD) used on its own in the context of a clinical trial, no cannabis-based medicinal products should be used for treating chronic pain. This is because the benefits they offer are very small compared with their high costs and so they can’t be considered a cost-effective use of NHS resources.

Paul Chrisp, director of the Centre for Guidelines at NICE, said: “In most cases, the draft guidance recommends that more research is carried out, echoing the recent call by the National Institute of Health Research for research proposals for these products. To that end NICE welcomes the recent suggestion from the House of Commons Health and Social Care Committee that companies should be encouraged to undertake or enable research into their medicinal cannabis products.”

The UK National Health Service (NHS) has also published a review aimed at assessing the barriers of prescribing cannabis-based medicinal products where safe and clinically appropriate.

This guide highlights the lack of clinical evidence about the long-term safety and effectiveness of medicinal cannabis. It suggests two clinical trials to test cannabis-based products.

The draft guidance will be open for public consultation until 5 September 2019.

Share via
Share via